2025-12-17 - Analysis Report
Here's a comprehensive analysis of Teladoc Health Inc (TDOC) based on the data provided.

**0. Report Summary**

Teladoc Health (TDOC) has significantly underperformed the S&P 500 (VOO) in recent years. The company faces challenges in profitability, reflected in negative ROE and inconsistent EPS. Recent news indicates concerns about valuation and insider selling, while analyst ratings suggest a "Hold" consensus.

**1. Return Rate Comparison**

*   **Ticker:** TDOC (Teladoc Health Inc) - A telehealth company providing virtual healthcare services.
*   **TDOC Cumulative Return:** -63.37%
*   **VOO (S&P 500) Cumulative Return:** 100.84%
*   **Divergence:** -165.3 (Relative Divergence: 0.2)

**Analysis:**

TDOC has dramatically underperformed the S&P 500. The significant negative divergence (-165.3) indicates a large difference in returns, with the relative divergence of 0.2 suggesting that this divergence is near its lowest point within the range of past performance. In plain language, TDOC's performance is exceptionally weak compared to the overall market.

**Alpha, Beta Analysis**

| Year       | CAGR   | MDD   | Alpha   | Beta   | Cap(B) |
|------------|--------|-------|---------|--------|--------|
| 2015-2017  | 77.0%  | 70.4% | 51.0%   | -0.1   | 6.2    |
| 2016-2018  | 101.0% | 69.4% | 86.0%   | -0.1   | 8.8    |
| 2017-2019  | 141.0% | 73.8% | 118.0%  | 0.3    | 14.9   |
| 2018-2020  | 105.0% | 80.9% | 81.0%   | 0.3    | 35.5   |
| 2019-2021  | -78.0% | 80.9% | -125.0% | 0.3    | 16.3   |
| 2020-2022  | -252.0%| 85.9% | -251.0% | -0.9   | 4.2    |
| 2021-2023  | -315.0%| 85.9% | -316.0% | -1.8   | 3.8    |
| 2022-2024  | -93.0% | 85.9% | -113.0% | -1.9   | 1.6    |
| 2023-2025  | -34.0% | 81.6% | -99.0%  | -0.8   | 1.3    |

**Analysis:**

*   **CAGR:** Shows a significant decline in compounded annual growth rate in recent periods.
*   **MDD:** Maximum Drawdown remains consistently high, indicating significant potential for losses.
*   **Alpha:** The consistently negative Alpha in recent years suggests TDOC is underperforming relative to its benchmark.
*   **Beta:** Beta has turned negative, implying an inverse correlation with the market, which is unusual and potentially concerning.
*   **Cap(B):** Market Cap has decreased dramatically.

**2. Recent Stock Price Fluctuations**

*   **Current Close:** $7.41
*   **Previous Close:** $7.34
*   **Change:** 0.95%
*   **5-day SMA:** 7.522
*   **20-day SMA:** 7.403
*   **60-day SMA:** 7.9578

**Analysis:**

The current price is slightly above the 20-day SMA but below the 5-day and 60-day SMAs. This suggests a mixed short-term trend. The slight increase in price compared to the previous close, with a change of 0.95%, is not significantly high, indicating no sharp rebound.

**3. Index Indicators**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment)
*   **RSI:** 47.95 (Neutral)
*   **PPO:** 0.3754
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (132 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** -0.1 (Short-term decline)
*   **Expected Return (%):** -10259.2%

**Analysis:**

*   **MRI:** A rating of 0.7 indicates a medium-risk investment, implying moderate volatility.
*   **RSI:** The RSI is near 50, suggesting neither overbought nor oversold conditions.
*   **PPO:** The Positive value suggests that the 12-period exponential moving average (EMA) is above the 26-period EMA, indicating upward momentum.
*   **Hybrid Signal:** Recommends buying with cash_0%, suggesting high conviction despite the risks, although the recommendation should be carefully considered given the context.
*   **Divergence Change:** Short-term decline in relative divergence indicates recent underperformance.
*   **Expected Return:** The extremely negative expected return suggests significant potential for losses in the long term.

**4. Recent News & Significant Events**

*   **Valuation Concerns:** Articles highlight reassessment and revisiting of Teladoc's valuation, suggesting potential overvaluation.
*   **ESOP Shelf Registration:** New ESOP shelf registration filing may dilute existing shareholder value.
*   **Insider Selling:** Multiple reports of insider selling (president, CEO) raise concerns about the company's prospects from those with inside knowledge.
*   **Stock Evaluation Report:** (TDOC) Stock Evaluation Report (TDOC:CA) might contain specific information that influences market participants.

**Analysis:**

The news flow is predominantly negative, with concerns about valuation, insider selling, and potential dilution. This negative sentiment could further pressure the stock price.

**4-2. Analyst Opinions**

*   **Consensus:** Hold
*   **Mean Rating:** 2.67 (~Hold)
*   **Opinions:** 22
*   **Target Price (avg/high/low):** 9.18 / 12.00 / 7.00

**Analysis:**

Analysts have a "Hold" consensus, indicating a lack of strong conviction in either direction. The average target price of $9.18 suggests potential upside, but the low target of $7.00 is near the current price, indicating little expected growth by some analysts. The absence of recent rating changes suggests that analysts' views are relatively stable.

**5. Recent Earnings Analysis**

| 날짜       | EPS    | 매출     |
|------------|--------|----------|
| 2025-10-30 | -0.28  | 0.63 B$  |
| 2025-07-30 | -0.19  | 0.63 B$  |
| 2025-05-01 | -0.53  | 0.63 B$  |
| 2024-10-31 | -0.19  | 0.64 B$  |
| 2025-10-30 | -0.19  | 0.64 B$  |

**Analysis:**

EPS has been consistently negative, indicating a lack of profitability. Revenue has remained relatively stable around $0.63-$0.64 billion. The recurring losses are concerning.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-09-30 | $0.63B  | 70.12%        |
| 2025-06-30 | $0.63B  | 69.85%        |
| 2025-03-31 | $0.63B  | 68.73%        |
| 2024-12-31 | $0.64B  | 70.50%        |
| 2024-09-30 | $0.64B  | 71.94%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE    |
|------------|---------|--------|
| 2025-09-30 | $1.39B  | -3.56% |
| 2025-06-30 | $1.42B  | -2.30% |
| 2025-03-31 | $1.43B  | -6.52% |
| 2024-12-31 | $1.49B  | -3.25% |
| 2024-09-30 | $1.51B  | -2.21% |

**Analysis:**

*   **Revenue:** Revenue is stable around $0.63-$0.64B per quarter.
*   **Profit Margin:** Relatively high profit margins, near 70%, indicate efficiency in operations, but don't translate to overall profitability due to other expenses.
*   **Equity:** Equity has been decreasing, suggesting financial strain.
*   **ROE:** Consistently negative ROE confirms the company's lack of profitability.

**7. Comprehensive Analysis**

Teladoc Health (TDOC) faces significant challenges. It has dramatically underperformed the S&P 500, has declining market cap with a concerning trend of negative earnings and ROE and is currently trading at $7.41.

*   **Negative Sentiment:** News about valuation concerns and insider selling is a major red flag.
*   **Financials:** While revenue is stable, consistent losses and decreasing equity are unsustainable.
*   **Technicals:** The price is below the 60-day SMA, and the negative divergence change suggests short-term weakness.
*   **Analyst Outlook:** A "Hold" rating reflects uncertainty.
*   **Hybrid Signal** The hybrid signal to "Buy" is concerning.

**Overall:** Given the financial performance, negative news flow, and underperformance relative to the market, investing in TDOC appears highly risky. It's imperative to carefully weigh the potential rewards against the high likelihood of further losses based on the available information.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.